Welcome to the Men's Health Knowledge Centre
As a disease topic Men's Health covers a broad set of issues affecting men of all ages. Some of the issues requiring greater focus and more thorough dissemination of information amongst the healthcare community, are those that have the potential to go undetected in the early stages. These include, hypogonadism and erectile dysfunction.
Early detection and more regular health checks of these diseases, not only improve prognosis and efficacy of treatment outcomes, but also quality of life.
- October 2014 - Treatment with testosterone improves cardiovascular risk factors in obese hypogonadal men, with or without type 2 diabetes mellitus
- In a prospective, observational, long-term study, 181 obese (BMI ≥30kg/m2) hypogonadal men, with and without type 2 diabetes mellitus (T2DM), were treated with testosterone undecanoate (TU) over 5 years. 40% (72 patients) also had T2DM
- After 5 years treatment with TU, there were significant anthropometric improvements with all patients having lost weight (mean reduction 18.86±0.36 kg), mean waist circumference decreased by 8.87% and BMI reduced by 16.44%
- There were similar reductions in anthropometric parameters in the diabetic subgroup. Mean body weight and BMI decreased by 15.97%, waist circumference decreased by 10.31 cm
- In the total study population there was an improvement in all cardiovascular risk factors and metabolic state. Significant improvements were seen in lipid profile, blood pressure, fasting glucose, HbA1c and liver function
- In the diabetic subgroup there were significant improvements in fasting glucose and HbA1c with comparatively greater decreases seen in the diabetic subgroup than in the general population. Fasting glucose decreased by 1.35 mmol/L and HbA1c decreased by 2.01%
- Treatment with TU was well tolerated. Increases in both haemoglobin (3.37%) and haematocrit (5.32%) remained within the normal range. Both parameters reached a plateau after 3 years of treatment with minor fluctuations thereafter
- Prostate volume increased slightly (<10%) over three years then stabilised, and mean prostate specific antigen increased over the 5 years by 0.18 ng/dL
- October 2014 - Efficacy and safety of injectable TU for the treatment of hypogonadism
- Injectable testosterone undecanoate is a long-acting testosterone formulation that has been available in EU for the treatment of male hypogonadism since 2003.
- Testosterone undecanoate treatment is well tolerated and no increased risk of prostate cancer or cardiovascular disease was observed, and has a more favorable pharmacokinetic and safety profile than older short-acting testosterone formulations.
- A meta-analysis of 33 intervention studies, of which 11 were randomized controlled trials (RCTs), using injectable testosterone undecanoate for treatment of hypogonadism, found the following main significant effects after a mean study duration of 2.8 years in men with a mean age of 57 years:
- reduction of BMI and body weight (mean weight loss; 5.88 kg, range 2.64-9.11 kg)
- reduction of waist circumference (mean waist loss; -7.11 cm, range -4.64 to -9.59 cm)
- reduction in fat mass; mean fat loss of -4.56% (range 3.36% to -5.76%)
- reduction of fasting glucose (mean -0.51 mmol/L, range -0.27 to 0.75)
- reduction of HbA1c levels (mean -0.68%, range -0.32% to -1,04%), and improvement of insulin resistance (measured by HOMA index)
- reduction of total cholesterol (mean -0.89 mmol/L, range -0.60 to -1.19 mmol/L)
- reduction of triglyceride levels (mean -0.44 mmol/L, range -0.24 to -0.63 mmol/L)
- increase in HDL levels (mean +0.15 mmol/L, range +0.08 to +0.23 mmol/L)
- reductions in systolic and diastolic blood pressure of 10 mmHg and 7 mmHg, respectively.
- improvement in sexual function, International Prostate Symptom Score (IPSS), bone mineral density and depressive symptoms.